CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
Natera, Inc. (NASDAQ:NTRA), a $19.2 billion market cap company currently trading at $141.07, saw its Chief Financial Officer Michael Burkes Brophy sell a total of $303,668 in company stock between July 22 and July 24. According to a Form 4 filing with the Securities and Exchange Commission, the sales involved 1,670 shares of common stock, with prices ranging from $139.2028 to $141.28. InvestingPro analysis indicates the stock appears overvalued at current levels, despite its impressive 38% return over the past year.
Specifically, on July 22, Brophy sold 920 shares at a price of $139.5816 per share. On July 23, the CFO sold 495 shares at $141.28 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 14, 2024. On July 24, Brophy sold two blocks of shares: 458 shares at a weighted average price of $139.2028, with prices ranging from $138.62 to $139.59, and 297 shares at a weighted average price of $139.9499, with prices ranging from $139.71 to $140.45. With Natera’s next earnings report due in 6 days, InvestingPro subscribers can access 8 additional key insights about the company’s financial health, which is currently rated as GOOD.
On July 22, Brophy also acquired 1,250 shares of Natera common stock upon the vesting of restricted stock units (RSUs). The exercise price for the RSUs was $0. Investors seeking deeper insights can access Natera’s comprehensive Pro Research Report, available exclusively on InvestingPro, which includes detailed analysis of the company’s valuation, growth prospects, and financial health metrics.
In other recent news, Natera has reported strong financial results for the first quarter of 2025, exceeding analysts’ expectations. The company posted an earnings per share (EPS) of -$0.50, better than the forecasted -$0.64, with revenue reaching $522 million, a 37% increase compared to the previous year. Natera’s recent developments also include an expansion of Medicare coverage for its Signatera MRD assay, now covering a wider range of cancers, which is expected to bolster its market position. Analysts at RBC Capital Markets have maintained an Outperform rating on Natera, with a price target of $251, citing effective commercial execution and revenue growth as key factors. Similarly, Leerink Partners reiterated their Outperform rating, emphasizing the significance of Medicare’s coverage decision for Natera’s WGS Signatera assay. Additionally, TD Cowen raised its price target for Natera to $200, highlighting a 13% increase in sales, driven by a rise in clinical volumes for the Signatera product. This growth is particularly notable amid concerns about potential volume issues faced by some of Natera’s peers. Overall, these developments reflect a positive outlook for Natera, supported by strong financial performance and strategic expansions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.